The in vivo series is developed using proprietary lipid nanoparticle (LNP) technology, systematically designed to meet diverse in vivo nucleic acid application needs, achieving high delivery efficiency, precise targeting, and excellent biocompatibility. One of the key features of this series of kits is its ease of use while maintaining a high transfection efficiency. It is designed for a simple, single-step encapsulation process that does not require any specific LNP encapsulation equipment.
The LipoSwift LNP - In Vivo Immune Cell Kit is an advanced solution for the in vivo targeted delivery of nucleic acids to key immune cell population. In the rapidly evolving fields of immunotherapy and vaccine development, the ability to specifically manipulate immune cells is crucial. Our in vivo immune cell Kit enables efficient delivery of nucleic acids, including mRNA, siRNA, saRNA, and circRNA, into critical immune cell populations such as macrophages, dendritic cells, and other antigen-presenting cells (APCs) directly within living organisms. By delivering functional payloads into these cells, researchers can modulate immune pathways, enhance antigen presentation, or reprogram immune responses for therapeutic purposes. This allows for a wide range of applications, from designing next-generation mRNA vaccines and developing novel cell therapies to studying the fundamental mechanisms of immune regulation.
This kit represents a significant step forward in our commitment to providing innovative tools for life sciences. It simplifies the complex process of in vivo immune cell targeting, making it a powerful resource for scientists working to develop safer and more effective immunotherapies and vaccines.
To validate the exceptional performance of the LipoSwift LNP - In Vivo Immune Cell Kit, we have conducted a series of rigorous in vivo studies. These results highlight the immune cell–targeting specificity of our product, particularly toward macrophages and dendritic cells.
